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Abstract
Background: To be fully activated platelets are dependent on two positive feedback loops; the
formation of thromboxane A2 by cyclooxygenase in the platelets and the release of ADP. We
wanted to evaluate the effect of aspirin on platelet function in patients with acute coronary
syndromes and we hypothesized that increased levels of ADP in patients with acute coronary
syndromes could contribute to aspirin resistance.
Methods: Platelet activity in 135 patients admitted for chest pain was assessed with PFA-100. An
epinephrine-collagen cartridge (EPI-COLL) was used for the detection of aspirin resistance
together with an ADP-collagen cartridge (ADP-COLL). ADP was measured with hplc from
antecubital vein samples. Three subgroups were compared: chest pain with no sign of cardiac
disease (NCD), NonST-elevation myocardial infarction (NSTEMI) and STEMI.
Results: Platelet activation was increased for the STEMI group compared NCD. Aspirin resistance
defined as <193 sec in EPI-COLL was 9.7 % in NCD, and increased to 26.0 % (n.s.) in NSTEMI and
83.3 % (p < 0.001) in STEMI. Chronic aspirin treatment significantly reduced platelet aggregation in
NCD and NSTEMI, but it had no effect in STEMI. Plasma levels of ADP were markedly increased
in STEMI (905 ± 721 nmol/l, p < 0.01), but not in NSTEMI (317 ± 245), compared to NCD (334 ±
271, mean ± SD). ADP levels correlated with increased platelet activity measured with ADP-COLL
(r = -0.30, p < 0.05). Aspirin resistant patients (EPI-COLL < 193 sec) had higher ADP levels
compared to aspirin responders (734 ± 807 vs. 282 ± 187 nmol/l, mean ± SD, p < 0.05).
Conclusion: Platelets are activated and aspirin resistance is more frequent in STEMI, probably due
to a general activation of platelets. ADP levels are increased in STEMI and correlates with platelet
activation. Increased levels of ADP could be one reason for increased platelet activity and aspirin
resistance.
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To be fully activated platelets are dependent on two posi-
tive feedback loops; the formation of thromboxane A2 by
cyclooxygenase in the platelets and the release of ADP
from dense platelet granules. Thromboxane A2 and ADP
then activates specific receptors on the extracellular side of
the platelet membrane. Therapeutic intervention aimed at
the first positive feedback loop by inhibiting cyclooxygen-
ase with aspirin is highly efficient in reducing death and
cardiovascular events by approximately 25% [1]. How-
ever, ADP may be even more important as evidenced by
the CAPRIE-study, in which the ADP receptor antagonist
clopidogrel was more beneficial than aspirin in reducing
cardiovascular events [2]. Furthermore, the CURE and
CREDO studies have established clopidogrel in combina-
tion with aspirin as a valuable treatment for acute coro-
nary syndromes [3,4].
The platelet inhibitory effect of aspirin varies and aspirin
resistance has been found in 9–45% of patients [5-7]. Lit-
tle is known about the clinical consequences of aspirin
resistance but lately two different studies indicate that
aspirin resistance could be associated with an increased
number of cardiovascular events [8,9].
Platelet activation is difficult to assess. Laboratory tests
available are either not sufficiently reliable or rather com-
plicated and therefore ineligible for clinical routine use. In
this study we used a novel platelet function test, PFA-100.
PFA-100 is an ex vivo assay of shear stress induced platelet
adhesion and aggregation in whole blood. It simulates an
injured blood vessel by a collagen-coated membrane
together with either epinephrine or ADP. It has been
found to be a sensitive test of aspirin resistance [6]. Aspi-
rin resistance has previously been studied in healthy con-
trols and in stable patients with a previous myocardial
infarction.
In this study we wanted to evaluate the effect of aspirin on
platelet function in patients with acute coronary syn-
dromes. Furthermore, we hypothesized that increased lev-
els of ADP in patients with acute coronary syndromes
could contribute to aspirin resistance.
Methods
Patients
135 patients were enrolled from patients admitted for
chest pain to the emergency ward, Lund University. Hos-
pital between 2001–2003. Patients with chest pain within
the last hour before admittance were eligible for inclu-
sion. Patients were defined as aspirin users or patients not
using aspirin the last three weeks (and not receiving aspi-
rin during transport to hospital). The use of aspirin was
defined as daily intake of aspirin for at least one week
before admittance. Most patients were on aspirin 75 mg
once daily, but a few (< 10%) were on 320 mg once daily.
Exclusion criteria were: ingestion of clopidogrel, dipyrida-
mole, nonsteroidal antiinflammatory drugs, heparin, low
molecular heparin, warfarin, receiving bolus dose of aspi-
rin on their way to hospital, platelet count <140 × 109/l,
hemoglobin <90 g/l, renal failure (creatinine >140 µmol/
l) or hemolysis in blood sample. The Human Ethics Com-
mittee of Lund University approved the project. All partic-
ipants gave informed written consent before enrolment.
Based on the diagnosis at discharge, three prespecified
subgroups were compared: chest pain with no sign of car-
diac disease (NCD), Non ST-elevation myocardial infarc-
tion (NSTEMI) and STEMI. The NCD group presented no
recent ECG changes and normal values of TNT. Exercise
test where appropriate before discharge were negative. A
minor number of patients in the NSTEMI and STEMI
group were on beta-blocker, ACE-inhibitors and Ca-chan-
nel blockers. However, the groups were to small for sub-
group analysis.
PFA-100 system testing
The PFA-100 system has been described in detail by
Kundu and co-workers [10]. The PFA-100 uses a disposa-
ble test cartridge that simulates an injured blood vessel.
The PFA-100 simulates primary haemostasis by flowing
whole blood at a high shear rate through an aperture (147
µm diameter) cut into a collagen-coated membrane
coated with either ADP (50 µg) or epinephrine (10 µg),
where it comes into contact with the membrane surface
and aggregate. A platelet plug forms, with occlusion of the
aperture and cessation of blood flow. The closure time
reflects platelet function in the sample evaluated. Shorter
closure times indicate increased platelet aggregation. Test-
ing was done in whole blood from antecubital vein sam-
ples anticoagulated with 3.8% sodium citrate. Samples
were obtained at admission in 135 patients. PFA-100 tests
were performed within 30 min after blood sampling,
within 1 hour after admission to hospital. The epine-
phrine-collagen cartridge (EPI-COLL) is sensitive to aspi-
rin and can be used for the detection of aspirin resistance
[6]. The ADP-collagen cartridge (ADP-COLL) is only
weakly sensitive to aspirin. Aspirin resistance was defined
as normal EPI-COLL closure times (<193 sec) based on
the 90% central interval in a normal population [6].
Nucleotide measurements
Nucleotides were measured in a total of 64 patients (16
patients with STEMI, 16 patients with NSTEMI and 32
patients with NCD). ADP was measured with hplc from
antecubital vein samples. Sampling was done at admis-
sion. 5 ml blood was added to tubes containing citrate
and immediately centrifuged for 10 min at 1200 G, 4°C.
Platelet contamination was excluded by Burker chamber
examination. The plasma was aspirated and mixed withPage 2 of 9
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and inactivate ectonucleotideases. After centrifugation the
protein free supernatant was frozen at -80°. Samples were
sent on dry ice by courier, to Department of Medicine,
University of North Carolina, School of Medicine, Chapel
Hill, USA for analysis.
Samples were thawed at room temperature and TCA was
extracted three times with six volumes of ethyl ether. Ethyl
ether was removed by gassing N2, and the resulting sam-
ples diluted in the corresponding nucleotide assay buffer
as indicated below.
Luciferin-luciferase assay
This assay has been previously described in detail else-
where [11]. Typically, extracts were diluted 1:20 in
HEPES-buffered Hanks Balanced Salt Solution (HBSS,
pH. 7.4) and a 30-µl sample was added to a test tube and
the volume adjusted to 300 µl with HPLC-grade H2O. The
luciferin-luciferase reaction mix (100 µl) was added to
tubes with a built-in injector into the light protected
chamber of an Auto-Lumat LB953 luminometer. Lumi-
nescence was subsequently recorded during 10 seconds
and compared against an ATP standard curve performed
in parallel. Luminescence was linear with slope of one
between 0.1 and 1000 nM ATP.
Derivatization of adenosine and adenine nucleotides
We have adopted and slightly modified a derivatization
protocol originally described by Levitt and co-workers
[12]. Sample extracts were incubated for 30 min at 72°C
in the presence of 1.0 M chloroacetaldehyde and 25 mM
Na2HPO4 (pH 4.0) in a 200-µl final volume. Samples
were transferred to ice, alkalinized with 50 µl 0.5 M
NH4HCO3, and analyzed by HPLC within 24 h. Identifi-
cation and quantification of ethenylated species were per-
formed with an automated Waters HPLC apparatus
equipped with a fluorescence detector. Derivatized sam-
ples were transferred to 0.7 ml plastic shell vials and kept
at 4°C in the sample injector rack. A 100 µl sample aliq-
uot was injected into a 250-mm, 10 µm Hamilton PRP-
X100 anion exchange column. The mobile phase (2 ml/
min, 30 % methanol) developed linearly from 0.250 to
0.275 M NH4HCO3 (pH 8.5) during the first 8 min,
remaining isocratic at 0.275 M NH4HCO3for additional 4
min. The column was subsequently rinsed for 3 min with
0.425 M NH4HCO3 in 30% methanol, and re-equilibrated
to the initial conditions for 15 min. Elution times (in
min) were: ε-ADO, 3.2; ε-AMP, 5.9; ε-ADP, 7.6, and ε-
ATP, 9.4.
Reagents
[14C]glucose-1P (300 mCi/mmol) and molecular biology
grade ATP and UTP were purchased from Amersham Phar-
macia Biotech (Piscataway, NJ). ADP, AMP, and adenos-
ine were from Roche Molecular Biochemicals
(Indianapolis, IN). Etheno-adenyl standards were from
Sigma (St. Louis, MO). Firefly luciferase and luciferin were
purchased from PharMingen International (San Diego,
CA). Other chemicals were of the highest purity available.
Calculation and statistics
Calculations and statistics were performed using the
GraphPad Prism 3.02 software. Values are presented as
mean ± SD. Statistical significance was accepted when P <
0.05 (two-tailed test). For continuous variables Kruskal-
Wallis test followed by Dunnett multiple comparisons
test was used. Spearman's rank correlation coefficient test
was used for regression analysis. Categorical variables
were compared using the Fisher exact test.
Ethics
The Ethics Committee of Lund University approved the
project. The study complies with the Declaration of Hel-
sinki. All patients gave written consent to participate in
the study.
Results
Patient characteristics
The clinical characteristics of the NCD, NSTEMI and
STEMI groups are shown in Table 1.
PFA-100
In patients without aspirin therapy there was an increased
platelet activation in the STEMI group compared to NCD
in the EPI-coll. NCD: 139 ± 44, NSTEMI: 121 ± 23 (n.s.),
STEMI: 99 ± 28 sec (p < 0.001, mean ± SD). (Fig 1a.) These
differences were also seen in patients on aspirin. NCD:
280 ± 41, NSTEMI: 243 ± 72 (n.s.), STEMI: 116 ± 56 sec
(p < 0.001, Fig 2a). Lower values indicate increased plate-
let activation. Similar results were observed with ADP-
COLL measurements (Fig 1b and 2b).
Chronic aspirin treatment (at least one week before
admission) significantly reduced platelet aggregation in
NCD and NSTEMI as seen by increased PFA-100 times for
EPI-COLL, but only in NCD for ADP-COLL (Fig 2). How-
ever, aspirin had no effect in either EPI-COLL or ADP-
COLL in patients with STEMI (Fig 2). Aspirin resistance
defined as <193 sec in EPI-COLL was 9.7 % in NCD, and
increased to 26.0 % in NSTEMI (n.s.) and 83.3 % in
STEMI(p < 0,001).
For PFA-100 measurements there were no significant cor-
relation with age, diabetes, hemoglobin, CKMB, troponin
T or platelet levels.
Nucleotide release
Plasma levels of ADP were markedly increased in STEMI
(905 ± 721 nmol/l, p < 0.01), but not in NSTEMI (317 ±Page 3 of 9
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Similar findings were found for other purines (ATP and
AMP). ADP levels correlated with increased platelet activ-
ity measured with ADP-COLL in the whole material (r = -
0.30, p < 0.05, Fig 4a). Similar results were seen for total
purines (r = -0.30, p < 0.05, Fig 4b). There was a non-sig-
nificant trend for EPI-COLL to correlate with both ADP
and total purines in patients with aspirin treatment (ADP:
r = -0.31, p = 0.09, total purines: r = -0.32, p = 0.09).
Aspirin resistant patients (EPI-COLL < 193 sec) had
higher ADP levels compared to aspirin responders (734 ±
807 vs. 282 ± 187 nmol/l, mean ± SD, p < 0.05), and
increased levels of total purines (1615 ± 1493 vs. 737 ±
408 nmol/l, mean ± SD, p < 0.05).
For purine measurements there were no significant corre-
lation with age, diabetes, haemoglobin, CKMB or tro-
ponin T levels. Platelet contamination was excluded by
cell counting and we did not see any correlations between
platelet counts and purine levels.
Nucleotide turnover is fast in whole blood due to ectonu-
cleotidases. ATP degradation was evaluated both in sam-
ples with endogenous ATP and in samples were ATP had
been added. The degradation was rapid in samples where
ATP was added with a T 1/2 of 5.2 min. Endogenous ATP
levels had a slower degradation rate, with a T 1/2 of
approximately 30 min.
Baseline levels of adenosine were markedly lower than
those of its nucleotides and barely detectable, most likely
due to both rapid uptake into the red blood cells and deg-
radation. This was because we have not included adenos-
ine deaminase and nucleoside transport inhibitors in the
perfused solution. The magnitude of changes in adenos-
ine levels could therefore not be studied but this was not
the aim of the study.
Discussion
In agreement with previous studies we found that plate-
lets are activated in acute coronary syndromes [13,14].
Furthermore, for the first time we could demonstrate a rise
in systemic levels of ADP and a decreased platelet inhibi-
tory effect of aspirin in patients with STEMI. It is possible
that the raised ADP level contributes to the increased
platelet activity and the reduced effect of aspirin
There is growing evidence that a significant number of
patients do not benefit from therapy with standard doses
of aspirin. Aspirin resistance however, is a poorly defined
term describing a number of conditions including the ina-
bility of aspirin to protect individuals from cardiovascular
events, to inhibit platelet aggregation measured with a
number of different methods and to inhibit thromboxane
A2 formation [15]. We found aspirin resistance levels in
controls (NCD) of 9.7%, which is in agreement with a
previous study that found 9.5% aspirin resistance using
PFA-100 [6]. It is also in agreement or even lower than
other methods that found frequencies of 9–45%. [6-8].
interestingly, we found increased frequency of aspirin
resistance in acute coronary syndromes rising from 9.7%
in controls to 26.0 % in NSTEMI (n.s.) and 83.3 % in
STEMI (p < 0,001). In fact, we could not see any signifi-
cant effect of aspirin on platelet aggregation measured
with PFA-100 in acute STEMI. Thus, in the situations
where the patients need the platelet inhibitory effect of
aspirin the most, the aspirin resistance is most frequent
The causative factors of aspirin resistance are still unclear.
Altman et al., (2004) described several possible mecha-
nisms behind aspirin resistance and the difficulty to inter-
pret and compare the results of different studies [16]. Both
the possibilities of inadequate doses of aspirin and throm-
boxane independent platelet aggregation mechanisms
have been discussed. In some patients aspirin resistance
could simply reflect non-compliance with drug therapy.
Weber et al., (2002) suggested several possible types of
aspirin resistance where one is linked to inability to
inhibit thromboxane formation [15]. Another possible
mechanism is classified as "pseudo resistance" since aspi-
rin exerted the expected pharmacodynamic effect of
inhibiting thromboxane formation but platelet aggrega-
tion was not inhibited. Hillarp et al., (2003) found that in
a series of 200 aspirin treated patients, none was found to
have unblocked cyclooxygenase activity [17]. Aspirin
resistance despite blocked cyclooxygenase activity has
been suggested to be explained by increased platelet sen-
sivity to ADP and collagen [5,18].
Our data show that aspirin resistance increases in STEMI.
This is probably due to a general activation of the plate-
lets, because platelet aggregation was also increased in
patients not treated with aspirin. The increased aspirin
resistance could be explained by increased activity of
important positive feedback systems such as ADP and
thromboxane [19], but also by an increase in vW factor
that are released from endothelial cells under high shear
stress [20].
Several studies have shown sufficient inhibition of plate-
let aggregation with the 75 mg dose [1,20]. Recently
though, a randomized study of 60 patients with stable
coronary artery disease showed that the effect of aspirin
was dose-dependent and the conclusion was that doses of
less than 100 mg of aspirin was less effective inhibiting
platelet aggregation than doses greater than 100 mg [22].
This could indicate that higher doses of aspirin could be
necessary to inhibit increased activity in the thromboxane
positive feedback system, but for the time being there isPage 4 of 9
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improve clinical outcome [1].
However, aspirin resistance could also be dependent on
increased activity of the ADP positive feedback system.
ADP is released by activated platelets, but also in the heart
from cardiac myocytes during ischemia, or from endothe-
lial cells, red blood cells and sympathetic nerves [22,23].
Erythrocytes are known to contain large amounts of ADP,
which may increase the platelet activity and modulate the
effect of aspirin [24]. It is known that nucleotides are
released from numerous cells during stress and exercise
[23]. The control group in this study was therefore chosen
to present pain and stress and it is our belief that this con-
trol group is more relevant for comparison than
unstressed healthy individuals to prove ischemia induced
increases in ADP levels.
For the first time we have demonstrated in man that ADP
levels are increased during myocardial infarction. It is pos-
sible that increased ADP levels during acute myocardial
ischemia could contribute to the increased frequency of
aspirin resistance. There are at least two subtypes of ADP
(a) Closure time measurements (epi-collagen) in NCD (no sign of ca diac disease), NSTEMI (non ST elevation myocar-dial in arction) and STEMI (ST elevation myoc rdial infarc-t o ) groupsFigure 1
(a) Closure time measurements (epi-collagen) in NCD (no 
sign of cardiac disease), NSTEMI (non ST elevation myocar-
dial infarction) and STEMI (ST elevation myocardial infarc-
tion) groups. (b) Closure time measurements (ADP-collagen) 
in the NCD, NSTEMI and STEMI groups. *** p < 0.001, com-
pared to NCD. Lower values indicate increased platelet 
activation.
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(a) Effect of chronic aspirin treament in the NCD (no sign of 
cardiac disease), NSTEMI (non ST elevation myocardial inf-
arction) and STEMI (ST elevation myocardial infarction) 
groups measured as closure time with the EPI-collagen car-
tridge. (b) Effects of aspirin in the NCD, NSTEMI and STEMI 
groups measured as closure time with the ADP-collagen car-
tridge. White bars: no aspirin treatment, black bars: aspirin 
treated patients. Values are expressed as mean values ± SD, 
*** p < 0.001, * p < 0.05, n.s. = not significant, compared to 
NCD. Lower values indicate increased platelet activation.
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Gi protein to adenylate cyclase. The P2Y12 receptor stimu-
lates platelet aggregation and has a high expression in
platelets [25,26]. Clopidogrel blocks the P2Y12 receptor
irreversibly and the value of this treatment has been estab-
lished by the CURE and CAPRIE studies. P2Y1 is a Gq pro-
tein linked ADP receptor expressed in platelets that
mediates shape change [25,26]. P2Y12 and thromboxane
receptors act via different intracellular second messenger
mechanisms, cAMP and inositol triphosphate (IP3),
respectively. This explains the additive clinical effect of
clopidogrel when it is combined with aspirin [3,4]. How-
ever, the P2Y1 receptor acts via the same second messenger
system as thromboxane (IP3). Thus, high levels of ADP
could replace thromboxane as stimulator of IP3 by activa-
tion of P2Y1 receptors. If ADP contributes to aspirin resist-
ance, it may not be sufficient to block the P2Y12 receptor.
It is possible that P2Y1 antagonists also will be necessary
to achieve inhibition of both the important intracellular
second messenger systems in the platelet.
Several studies have shown a higher incidence of cardio-
vascular events in patients reported to be aspirin resistant.
Gum et al found that aspirin resistance was associated
with an increased risk of death, myocardial infarction or
cerebrovascular accident compared to aspirin sensitive
patients (24% vs. 10%) [8]. Grotemeyer and colleagues
described in 1993 a 40% risk for major events (stroke,
myocardial infarction or vascular death) for aspirin resist-
ant patients compared to a 4% risk in the aspirin
responder group [7]. Eikelboom et al., (2002) recently
reported that elevated urine concentrations of 11-dehydro
thromboxane B2 could predict the risk of myocardial inf-
arction [9]. Further prospective studies will be needed to
Plasma concentrations of extracellular purines in NCD (no sign of cardiac disease), NSTEMI (non ST elevation myocardial inf-arction) a d STEMI (ST el vation myocard al infarction) groups expressed as mean values ± SD. * p < 0.05, ** p < 0.01, com-pared to NCDFigure 3
Plasma concentrations of extracellular purines in NCD (no sign of cardiac disease), NSTEMI (non ST elevation myocardial inf-
arction) and STEMI (ST elevation myocardial infarction) groups expressed as mean values ± SD. * p < 0.05, ** p < 0.01, com-
pared to NCD.
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tification of patients with increased risk of myocardial inf-
arction in the future. Why did the patients with aspirin
resistance have higher ADP levels? It is possible that this
was the result of a more pronounced cardiac ischemia.
However, ADP levels did not correlate with either CKMB
or troponin T levels. Another explanation could be that
subgroups of patients are more dependent on the ADP
positive feedback system than on the thromboxane sys-
tem, and therefore more aspirin resistant. Then our find-
ing of increased ADP levels may reflect an increased ADP
release from platelets. These patents may benefit more
from inhibitors of ADP mediated platelet activation than
aspirin.
Limitations of the study
Patients found to be aspirin resistant were not all con-
firmed by a second test with the PFA-100. However, this
was not possible in the NSTEMI and STEMI groups since
they were treated early with clopidogrel, enoxaparin or
GPIIb/IIIa-blockers that influence the PFA-100 measure-
ments. ADP measurements are difficult because of the
rapid degradation by ectonucleotidases being present pre-
dominantly on endothelial cells. We found a half-life of
5.2 min when ATP was added to our blood samples in
vitro, however endogenous levels of ATP levels were more
stable. The baseline ATP levels were in the micromolar
range, which is similar to previously reported levels of cir-
culating ATP in man [27]. Our sampling of venous blood
in the antecubital vein is clearly not optimal to detect
purine release in the heart. The released purine has passed
both the lung and systemic circulation resulting in a deg-
radation chain from ATP, ADP, AMP to adenosine. Ade-
nosine is then rapidly taking up by the red blood cells.
Thus the adenosine levels were barely detectable. It is our
belief that blood sampling directly from heart veins
(a) Correlation between extracellular total purine levels and platelet activity measured as closure time with the ADP-COLL c rtridgeFigure 4
(a) Correlation between extracellular total purine levels and platelet activity measured as closure time with the ADP-COLL 
cartridge. (b) Correlation between extracellular ADP levels and platelet activity measured as closure time with the ADP-COLL 
cartridge.
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in the NSTEMI and STEMI groups and probably also bet-
ter correlations with platelet activity. Another limitation is
that the correlation analysis had to be done on the whole
material since the subgroups were too small for separate
correlation analysis.
Conclusion
Platelets are activated and aspirin resistance is more fre-
quent in STEMI, probably due to a general activation of
platelets. ADP levels are increased in STEMI and correlates
with platelet activation. Increased levels of ADP could be
one reason for increased platelet activity and aspirin
resistance.
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